Search

everythinglearnresearchcommunity

for

Search:↓

A five-month-old boy with Omenn syndrome successfully recovered after a stem cell transplant with reduced intensity conditioning.

Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.

Skin reactions are a common reason for emergency visits due to drug allergies, with some severe cases needing intensive care.

Newborn screening and gene therapy are expected to improve outcomes for Omenn syndrome patients.

A woman on immunosuppressants developed two rare scalp conditions, which improved with specific treatments.

Certain gene variations may increase the risk and severity of alopecia areata.

The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.

Vitiligo treatment requires a personalized mix of therapies to restore skin color and improve life quality.

A combined treatment with microneedling and vitamin D3 led to complete hair regrowth in a woman with stubborn patch alopecia areata.

An 11-year-old child with total hair loss may have a genetic autoimmune disease, and the outlook for hair regrowth is not good.

COVID-19 may trigger or worsen rapid hair loss in alopecia areata.

The CRH/CRH-R1 system might be involved in causing lichen planus.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.

Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

Hair follicle development is controlled by interactions between skin tissues and specific molecular signals.

Frontal fibrosing alopecia is a hair loss condition in postmenopausal women, similar to lichen planopilaris, with ineffective treatments.

Fat tissue-derived cells show promise for repairing body tissues, but more research and regulation are needed for safe use.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.

Skin's Regulatory T cells are crucial for maintaining skin health and could be targeted to treat immune-related skin diseases and cancer.

Alopecia areata can cause unpredictable hair loss, and treatments like corticosteroids and minoxidil may help but have varying side effects.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.